LFCR — Lifecore Biomedical Income Statement
0.000.00%
- $272.88m
- $395.05m
- $128.87m
- 24
- 37
- 95
- 51
Annual income statement for Lifecore Biomedical, fiscal year end - May 25th, USD millions except per share, conversion factor applied.
R2021 May 30th | R2022 May 29th | 2023 May 28th | 2024 May 26th | 2025 May 25th | |
---|---|---|---|---|---|
Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 101 | 111 | 103 | 128 | 129 |
Cost of Revenue | |||||
Gross Profit | 38.9 | 39.1 | 28 | 41.9 | 40.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 111 | 123 | 149 | 137 | 146 |
Operating Profit | -9.93 | -11.8 | -45.5 | -8.84 | -17.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29.8 | -20.7 | -63.9 | 9.51 | -38.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.4 | -15.5 | -64.2 | 9.33 | -38.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -32.3 | -117 | -99.6 | 12 | -38.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -32.3 | -117 | -99.6 | 12 | -44.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.119 | 1.55 | -1.22 | 0.606 | -1.18 |